Skip to main content
Editorial27 June 2016
Editorial: NK Cell-Based Cancer Immunotherapy
Francisco Borrego, Susana Larrucea, Rafael Solanaand Raquel Tarazona

Innate and adaptive immunity cooperate to eliminate tumours. However, when infrequent cancer cell variants are not destroyed, tumour growth and immunosurveillance enter into a dynamic equilibrium until cancer cells evade the immune system, at which point malignancies appear clinically as a consequence. Therapies designed to induce potent antitumor responses by harnessing the power of the immune system are an appealing strategy to control tumour growth. Natural killer (NK) cells are innate lymphocytes that play a pivotal role in host immunity against cancer. The activity of NK cells is finely tuned by the balance between the signals that emanate from inhibitory and activating receptors. Inhibitory receptors, like killer-cell immunoglobulin-like receptor (KIR) and CD94/NK Group 2 member A (NKG2A), recognize human leukocyte (HLA) class I molecules whose expression is often altered on tumour cells. NK cells recognize tumour cells by activating receptors like natural cytotoxicity receptors (NCRs) and NKG2D, which sense the changed expression of their ligands on the cancer cell surface. Providing important insights, the past fifteen years have witnessed an explosion of research into the biology and clinical applications of NK cells. Current NK cell-based cancer immunotherapy aims to reverse the tumour-induced NK cell dysfunction that is observed in patients with cancer and to increase and sustain NK cell effector functions. Therapies involving NK cells may either activate endogenous NK cells or involve transfer of exogenous cells by hematopoietic stem cell transplantation (HSCT) or adoptive cell therapy.

In this Research Topic, we have collected several articles that highlight the exciting potential that NK cells exhibit as an effective tool in cancer immunotherapy. We open the Research Topic with two articles that describe NK cell surface receptors involved in the recognition of tumour target cells. Chester et al. briefly describe NK-cell tumour interactions and the three most important mechanisms of how NK cells kill target cells, i.e. natural killing, antibody-dependent cell-mediated cytotoxicity (ADCC) and death receptor-induced apoptosis, and follow with a description of the best studied activating and inhibitory receptors involved in tumour cell recognition, along with the ability of agonistic monoclonal antibodies (mAbs) specific for co-stimulatory molecules such as CD137 and OX40 (1). Horton and Mathew focus their review on NCRs, with a special attention to NKp44 and its dual activating and inhibitory function following recognition of different ligands (2). They suggest that NCRs serve as receptors for damage-associated molecular pattern (DAMP) molecules in association with HLA class I molecules, heparan sulfate proteoglycans (HSPGs) or other co-ligands and therefore regulate NK cell activity (2). A better understanding of the tumour immunosuppressive microenvironment is very important to design efficient NK cell-based therapies. Hasmim et al. review the cell types within the tumour that are involved in the suppression of NK cells, including M2-polarized macrophages, myeloid-derived suppressor cells (MDSC), regulatory T cells (Treg) and fibroblasts, and how the microenvironmental hypoxia that is characteristic of solid tumours inhibit NK cell functions (3).

Next, there is a group of articles that provide a general vision of how to obtain and harness NK cells to fight tumours. Dahlberg et al., Domogala et al., Pittari et al., and Rezvani et al., have reviewed the different cellular sources and methods to isolate, differentiate, genetically engineer, expand and activate ex vivo and in vivo NK cells, including autologous and allogeneic NK cells and NK cell lines (4-7). Sources to generate NK cell products include, in addition to NK cell lines, NK cells from peripheral blood or from cord blood and NK cells differentiated from CD34+ hematopoietic precursors or pluripotent stem cells (embryonic stem cells or induced pluripotent stem cells) (4-7). In general, adoptive NK cell-based therapy has been more successful in the treatment of haematological tumours than in patients with solid tumours, and the use of tools aimed to reverse the immune-suppressive tumour microenvironment significantly will improve the efficacy of this type of therapy (4, 6, 7). A cell product termed cytokine-induced killer (CIK) cells which possess phenotypic and functional features of both NK cells and T cells is also described by Pittari et al. (6).

Like T cells, genetic manipulation of NK cells is emerging as a promising tool to increase their anti-tumour activity. Chimeric antigen receptors (CARs) consist of an extracellular domain, generally a small chain variable fragment, specific for a tumour antigen that is linked with one or more intracellular domains able to induce activation signals. Here, Hermanson and Kaufman extensively review the CAR constructs with different intracellular activation domains that have been described to date in NK cells from several sources, suggesting that depending on the tumour type and/or target antigen, different CAR constructs may be required for optimal activation of NK cells (8). Carlsten and Childs review the advantages and challenges of methods to genetically modify NK cells, and give an overview of different strategies to reprogram NK cells with the objective to improve the persistence and expansion of infused cells, to enhance the migration to the tumours and to improve their cytotoxicity (9). Cell lines, like NK-92, could be an alternative to NK cells from patients or allogeneic donors. They could easily be expanded in culture, genetically manipulated and may represent an off-the-shelf product ready for use. Klingemann et al. review that NK-92 is the only cell line that has been studied in clinical trials with clinically significant responses and minimal adverse reactions (10).

In contrast to normal cells, many tumour cells express heat-shock protein 70 (Hsp70) at the cell surface and gets released into the circulation. Membrane Hsp70 (mHsp70) correlates with high aggressiveness of the tumours. In this Research Topic, Gunther et al. describe that patients with squamous cell and adeno non-small cell lung cancer (NSCLC) exhibited high levels of serum Hsp70. Furthermore, they found a positive correlation between serum levels of Hsp70 with gross tumour volume and an inverse correlation with CD69+/CD94+ NK cells in squamous NSCLC, suggesting that activated NK cells somehow may be involved in the control of tumour growth (11). The same group have previously found in preclinical studies that NK cells activated with a naturally occurring Hsp70 peptide (TKD) and IL-2 are able of specifically kill mHsp70-expressing tumours but not mHsp70 negative ones. Here, they summarize a phase I clinical trial of TKD/IL-2 stimulated autologous NK cells with NSCLC and describe an ongoing phase II clinical trial of TKD/IL-2 stimulated NK cells for the treatment of patients with NSCLC following radiochemotherapy (12).

The mechanism of action of many therapeutic mAbs for cancer treatment involves, at least partially, ADCC through FcγRIIIA/CD16a. Many studies have shown that the clinical outcome after treatment of patients with mAbs is correlated with polymorphisms at the FCGR3A gene, which encodes for FcγRIIIA/CD16a, that affect the binding affinity to mAbs. Wang et al. review some of the current therapeutic mAbs that are being used in the clinic, and strategies that increase their ADCC, such as modifying the glycosilation patterns of the mAbs, combining them with other mAbs, radiation therapy, matrix metalloproteases inhibitors or cytokines, and by designing new molecular entities such as immunocytokines and bi-specific antibodies (13). Cetuximab, an anti-epidermal growth factor receptor (EGFR) mAb, exerts ADCC against EGFR+ target cells. Klöss et al. show that patients with head and neck squamous cell carcinomas (HNSCCs) have elevated levels of soluble major histocompatibility complex class I chain-related peptide A (sMICA) and transforming growth factor beta 1 (TGF-β1) in serum, which are responsible for the impaired NK cell effector functions and decreased NKG2D expression. They show that cetuximab restores the NK cell-mediated killing of sMICA-inhibited patient NK cells against HNSCC cells via ADCC and enhances tumour infiltration of NK cells in HNSCC tumour spheroids (14).

Autologous hematopoietic stem cell transplantation (autoHSCT) is a therapeutic indication for multiple myeloma or malignant lymphoma, and it has been shown that the reconstitution levels of the NK cell pool after autoHSCT has a prognostic value. Jacobs et al. have studied the phenotype and function of NK cells after autoHSCT. They found that CD56++ NK cells were the major subset 1-2 days after leukocyte regeneration (>1000 leukocytes/μl) and that is characterized by a high expression of CD57 and KIRs, which is age dependent, and that are able to degranulate and produce cytokines after tumour interaction (15). On the other hand, preclinical and clinical data have demonstrated that in the context of haploidentical T-cell depleted HSCT, alloreactive NK cells are able to exert a very important anti-tumour activity, with no increased incidence of graft versus host disease (GVDH), and that mature alloreactive NK cells can be safely infused into patients. The KIR-HLA class I mismatch between donor and recipient in the graft versus leukemia (GVL) direction has demonstrated to enhance the anti-tumour activity of NK cells. In this Research Topic, two articles by Lim et al. and Ruggeri et al. review the present and future of alloreactive NK cells for tumour treatment, mostly acute myeloid leukemia (AML), in the context of allogeneic HSCT and infusions of alloreactive purified NK cells (16, 17). These are emerging as safe and potent effectors against tumours.

Based on their expressed pattern of cell surface receptors, NK cells are divided in subsets that are able to mediate different effector functions and are characterized by distinct homing properties. Gismondi et al. have reviewed this issue, suggesting that for improved and more efficient NK cell-based therapies it is necessary to identify, isolate, expand and administer NK cell subsets that exhibit increased effector functions and have the adequate homing capabilities to reach the tumours (18). Chretien et al., with an automated procedure using the FLOCK algorithm and a panel of three markers (CD56, CD57 and KIRs), define five maturation stages of NK cells from human peripheral blood. By analysing a cohort of healthy volunteers and another cohort of patients with AML, they found that the latter displayed marked differences compared to healthy donors. Moreover, within the AML cohort, it was possible to define three distinct groups of patients according to their maturation profiles, which might be useful for prognostic purposes (19). Tarazona et al. have reviewed the current knowledge about the role of NK cells on the recognition and elimination of melanoma cells and the strategies against melanoma based on NK cells. In vitro experiments, in vivo data from murine models and observations from melanoma patients indicate that NK cells have a role in the immune response against melanoma. NK cell-based therapies against melanoma include, among others, modulation of NK cell responses by administration of cytokines, treatment with checkpoint inhibitors and bi-specific antibodies, and by adoptive NK cell therapy with autologous or allogeneic NK cells and NK cell lines, genetically modified or not (20).

Finally, we want to express our gratitude to all the authors that have contributed to this Research Topic and to the reviewers for their magnificent job. We hope that the reader will find this Research Topic motivating and helpful. We invite you to read the following articles and immerse yourself in the interesting world of NK cell-based cancer immunotherapy.

5,855 views

18 citations

There is compelling clinical and experimental evidence to suggest natural killer (NK) cells play a critical role in the recognition and eradication of tumors. Efforts at using NK cells as antitumor agents began over two decades ago, but recent advances in elucidating NK cell biology have accelerated the development of NK cell-targeting therapeutics. NK cell activation and the triggering of effector functions is governed by a complex set of activating and inhibitory receptors. In the early phases of cancer immune surveillance, NK cells directly identify and lyse cancer cells. Nascent transformed cells elicit NK cell activation and are eliminated. However, as tumors progress, cancerous cells develop immunosuppressive mechanisms that circumvent NK cell-mediated killing, allowing for tumor escape and proliferation. Therapeutic intervention aims to reverse tumor-induced NK cell suppression and sustain NK cells’ tumorlytic capacities. Here, we review tumor-NK cell interactions, discuss the mechanisms by which NK cells generate an antitumor immune response, and discuss NK cell-based therapeutic strategies targeting activating, inhibitory, and costimulatory receptors.

33,473 views

185 citations

REVIEW
7 January 2016
Natural Killer Cell Recognition of Melanoma: New Clues for a More Effective Immunotherapy
Raquel Tarazona, 1 more and Rafael Solana

13,904 views

51 citations

ORIGINAL RESEARCH
24 November 2015
NK Cell Subgroups, Phenotype, and Functions After Autologous Stem Cell Transplantation
Benedikt Jacobs, 4 more and Evelyn Ullrich

7,401 views

25 citations

Natural killer (NK) cells are essential components of the innate immune system and play a critical role in host immunity against cancer. Recent progress in our understanding of NK cell immunobiology has paved the way for novel NK cell-based therapeutic strategies for the treatment of cancer. In this review, we will focus on recent advances in the field of NK cell immunotherapy, including augmentation of antibody-dependent cellular cytotoxicity, manipulation of receptor-mediated activation, and adoptive immunotherapy with ex vivo expanded, chimeric antigen receptor (CAR) engineered or engager-modified NK cells. In contrast to T lymphocytes, donor NK cells do not attack non-hematopoietic tissues, suggesting that an NK-mediated anti-tumor effect can be achieved in the absence of graft-versus-host disease. Despite reports of clinical efficacy, a number of factors limit the application of NK cell immunotherapy for the treatment of cancer such as the failure of infused NK cells to expand and persist in vivo. Therefore efforts to enhance the therapeutic benefit of NK cell-based immunotherapy by developing strategies to manipulate the NK cell product, host factors and tumor targets are the subject of intense research. In the preclinical setting, genetic engineering of NK cells to express CARs to redirect their antitumor specificity has shown significant promise. Given the short lifespan and potent cytolytic function of mature NK cells, they are attractive candidate effector cells to express CARs for adoptive immunotherapies. Another innovative approach to redirect NK cytotoxicity towards tumor cells is to create either bispecific or trispecific antibodies, thus augmenting cytotoxicity against tumor-associated antigens. These are exciting times for the study of NK cells; with recent advances in the field of NK cell biology and translational research, it is likely that NK cell immunotherapy will move to the forefront of cancer immunotherapy over the next few years.

50,581 views

274 citations

ORIGINAL RESEARCH
6 November 2015
Increased NK Cell Maturation in Patients with Acute Myeloid Leukemia
Anne-Sophie Chretien, 8 more and Daniel Olive

6,407 views

27 citations

ORIGINAL RESEARCH
2 November 2015
Cetuximab Reconstitutes Pro-Inflammatory Cytokine Secretions and Tumor-Infiltrating Capabilities of sMICA-Inhibited NK Cells in HNSCC Tumor Spheroids

7,236 views

40 citations

ORIGINAL RESEARCH
2 November 2015
Correlation of Hsp70 Serum Levels with Gross Tumor Volume and Composition of Lymphocyte Subpopulations in Patients with Squamous Cell and Adeno Non-Small Cell Lung Cancer
Sophie Gunther, 9 more and Gabriele Multhoff

8,621 views

86 citations

Natural killer (NK) cells play a major role in cancer immunotherapies that involve tumor-antigen targeting by monoclonal antibodies (mAbs). NK cells express a variety of activating and inhibitory receptors that serve to regulate the function and activity of the cells. In the context of targeting cells, NK cells can be “specifically activated” through certain Fc receptors that are expressed on their cell surface. NK cells can express FcγRIIIA and/or FcγRIIC, which can bind to the Fc portion of immunoglobulins, transmitting activating signals within NK cells. Once activated through Fc receptors by antibodies bound to target cells, NK cells are able to lyse target cells without priming, and secrete cytokines like interferon gamma to recruit adaptive immune cells. This antibody-dependent cell-mediated cytotoxicity (ADCC) of tumor cells is utilized in the treatment of various cancers overexpressing unique antigens, such as neuroblastoma, breast cancer, B cell lymphoma, and others. NK cells also express a family of receptors called Killer Immunoglobulin-like Receptors (KIRs), which regulate the function and response of NK cells towards target cells through their interaction with their cognate ligands that are expressed on tumor cells. Genetic polymorphisms in KIR and KIR ligands, as well as FcγRs may influence NK cell responsiveness in conjunction with mAb immunotherapies. This review focuses on current therapeutic mAbs, different strategies to augment the anti-tumor efficacy of ADCC, and genotypic factors that may influence patient responses to antibody-dependent immunotherapies.

71,505 views

561 citations

REVIEW
23 September 2015
Critical Role of Tumor Microenvironment in Shaping NK Cell Functions: Implication of Hypoxic Stress
Meriem Hasmim, 5 more and Salem Chouaib

15,809 views

132 citations

Genetic Manipulation of NK Cells for Cancer Immunotherapy: Techniques and Clinical Implications
Given their rapid and efficient capacity to recognize and kill tumor cells, Natural killer (NK) cells represent a unique immune cell to genetically reprogram in an effort to improve the outcome of cell-based cancer immunotherapy. However, technical and biological challenges associated with gene delivery into NK cells have significantly tempered this approach. Recent advances in viral transduction and electroporation have now allowed detailed characterization of genetically modified NK cells and provided a better understanding for how these cells can be utilized in the clinic to optimize their capacity to induce tumor regression in vivo. Improving NK cell persistence in vivo via autocrine IL-2 and IL-15 stimulation, enhancing tumor targeting by silencing inhibitory NK cell receptors such as NKG2A, and redirecting tumor killing via chimeric antigen receptors, all represent approaches that hold promise in preclinical studies. This review focuses on available methods for genetic reprogramming of NK cells and the advantages and challenges associated with each method. It also gives an overview of strategies for genetic reprogramming of NK cells that have been evaluated to date and an outlook on how these strategies may be best utilized in clinical protocols. With the recent advances in our understanding of the complex biological networks that regulate the ability of NK cells to target and kill tumors in vivo, we foresee genetic engineering as an obligatory pathway required to exploit the full potential of NK-cell based immunotherapy in the clinic.

30,181 views

232 citations

MINI REVIEW
3 June 2015
Present and Future of Allogeneic Natural Killer Cell Therapy
Okjae Lim, 2 more and Eui-Cheol Shin

23,585 views

85 citations

REVIEW
15 April 2015
Heat Shock Protein 70 (Hsp70) Peptide Activated Natural Killer (NK) Cells for the Treatment of Patients with Non-Small Cell Lung Cancer (NSCLC) after Radiochemotherapy (RCTx) – From Preclinical Studies to a Clinical Phase II Trial
Hanno M. Specht, 17 more and Gabriele Multhoff

15,588 views

102 citations